The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study

Inclusion Criteria

• •1. Children with pediatric lymphoma (HL and NHL) that met the criteria and required treatment upon histological and pathological diagnosis;
• •2. Age: \< 18 years old;
• •3. The working status of the Eastern Cooperative Oncology Group (ECOG) (PS) : 0-2 points;
• •4. CT/MRI measurable lesion was defined as the longest diameter of at least 1 lymph node ≥ 1.5cm, and it was clearly measurable in 2 vertical directions;
• •5. Complete clinical laboratory examination and pathological examination information;
• •6. Patients can be evaluated on time, and the required samples can be obtained throughout the testing process;
• •7. After the patient is informed of the project, the informed consent signed by the patient or his legal representative is obtained.